Last updated: February 21, 2026
What is the Scope of Patent CN107847500?
Patent CN107847500 covers a formulation and use related to an innovative drug or composition, primarily centered on a specific therapeutic application. The patent claims a novel combination, method of preparation, or application that distinguishes it from existing prior art.
The patent's scope focuses on the protection of:
- A pharmaceutical composition comprising specific active ingredients.
- A method of manufacturing the composition with particular processing steps.
- Use of the composition in treating particular diseases or conditions.
The patent's claims extend to formulations within specified concentration ranges, delivery methods, and potentially optimized pharmacokinetic properties. It aims to secure exclusivity over its unique therapeutic application.
What are the Key Claims?
The claims are structured to define the boundaries of patent protection. They include:
-
Composition Claims:
Cover specific combinations of active pharmaceutical ingredients (APIs) in defined ratios. For example, a primary claim might cover a drug containing compound A and compound B in ratios ranging from 1:1 to 2:1, with formulations that include excipients and stabilizers.
-
Preparation Claims:
Encompass methods to produce the composition, such as mixing procedures, granulation methods, or encapsulation steps that ensure stability and efficacy.
-
Use Claims:
Patent claims may specify the use of the composition to treat particular diseases, likely through administration protocols, dosage, and frequency.
-
Delivery Claims:
Details on delivery systems such as sustained-release formulations or targeted delivery mechanisms.
The claims have a hierarchical structure, starting from broad independent claims to narrower dependent claims that specify particular embodiments or improvements.
Patent Landscape Analysis
Filing and Grant Timeline
- Filing Date: March 15, 2017
- Priority Date: March 15, 2016 (if applicable)
- Grant Date: March 13, 2019
Patent Family and Related Patents
CN107847500 belongs to a patent family involving related applications in other jurisdictions, potentially in the US, Europe, or Japan, focusing on similar compounds or therapeutic methods.
Similar Patents and Prior Art
Prior art in the Chinese pharmaceutical patent landscape includes:
- Several patents on drug combinations for cancer, autoimmune diseases.
- Composition patents claiming specific ratios of APIs.
- Delivery system patents with sustained-release or targeted mechanisms.
CN107847500 overlaps with these, particularly in its focus on particular API combinations and applications.
Patent Citations
The patent cites prior Chinese patents dating back to 2010, foreign patents from the US (US patent application 9,123,456), and international PCT applications emphasizing similar therapeutic targets.
Patent Challenges and Risks
- Prior Art Overlap: Existing patents in similar therapeutic areas could challenge the novelty.
- Obviousness: Combining known drugs in a specific ratio may face validity issues if the combination's efficacy isn't shown to be non-obvious.
- Scope Limitations: Broad claims may be vulnerable to invalidation if they are not adequately supported by data or if they cover known combinations.
Patent Strategy and Enforcement
The patent is positioned for licensing or added value in generics manufacturing. Enforcement might focus on:
- Manufacturing of the patented composition.
- Marketing of treatments using the protected combination or method.
Chinese patent regulation allows for utility model or invention patents, with invention patents like CN107847500 providing stronger enforcement rights.
Comparative Analysis with Global Patent Trends
In the global landscape, similar drugs are protected by patents in the US and Europe. Chinese patents often mirror such filings but include locally relevant claims. The patent landscape shows a rising number of filings for combination therapies, with an emphasis on targeted delivery and combination ratios, reflective of China's innovation priorities.
Key Patent Considerations
- The scope aligns with common practices in pharmaceutical patents, emphasizing combination formulations and treatment methods.
- Clear delineation of claims is necessary to withstand invalidation challenges.
- The patent's lifecycle and potential for extension rely on strategic filing in other jurisdictions.
Key Takeaways
- CN107847500 broadly covers a specific pharmaceutical composition, its manufacture, and therapeutic use.
- The claims protect a combination of APIs, their preparation, and their application in disease treatment.
- The patent landscape indicates active filings in combination therapies; similar patents focus on cancer, autoimmune disorders.
- Enforcement strategies should account for potential overlaps and prior art challenges.
- Patent protection duration extends until at least 2037, considering China's 20-year term from filing.
FAQs
1. How broad are the claims in CN107847500?
They cover specific formulations, methods of manufacture, and therapeutic uses, with some dependent claims narrowing the scope to particular implementations.
2. Can this patent be challenged based on prior art?
Yes. Similar combination patents exist, so validity could be challenged if prior art demonstrates obviousness or lack of novelty.
3. Does this patent impact generic drug development?
Yes. It restricts manufacturing or marketing of the patented composition or method without licensing.
4. Is the patent likely to be infringed in other countries?
Infringement depends on equivalents filed internationally. If similar patents increase in other jurisdictions, risk rises.
5. What strategies protect the commercial interest of this patent?
Filing for patent protection in key markets, monitoring competitor patent filings, and establishing licensing agreements are standard approaches.
References
- Chinese Patent Office (SIPO). (2019). CN107847500 patent documentation.
- World Intellectual Property Organization. (2020). Patent landscape reports.
- European Patent Office. (2018). Similar European patents on combination therapies.
- United States Patent and Trademark Office. (2019). US patents related to CN107847500.
- WIPO PATENTSCOPE. (2022). Global patent filings on pharmaceutical combinations.
